The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC).
Gregory Russell Pond
No relevant relationships to disclose
Andrew J. Armstrong
Honoraria - Janssen-Ortho; Sanofi
Research Funding - Sanofi
Brian A. Wood
Employment or Leadership Position - Ascenta Therapeutics
Stock Ownership - Ascenta Therapeutics
Lance Howard Leopold
Employment or Leadership Position - Ascenta Therapeutics
Stock Ownership - Ascenta Therapeutics
Matt D. Galsky
No relevant relationships to disclose
Guru Sonpavde
Honoraria - Sanofi
Research Funding - Ascenta Therapeutics; Sanofi